UBR7 E3 Ligase Suppresses Interferon-β Mediated Immune Signaling by Targeting Sp110 in Hepatitis B Virus-Induced Hepatocellular Carcinoma.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: ACS Publications Country of Publication: United States NLM ID: 101654580 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2373-8227 (Electronic) Linking ISSN: 23738227 NLM ISO Abbreviation: ACS Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: Washington, DC : ACS Publications, [2015]-
    • Subject Terms:
      Carcinoma, Hepatocellular*/virology ; Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/immunology ; Ubiquitin-Protein Ligases*/genetics ; Ubiquitin-Protein Ligases*/metabolism ; Liver Neoplasms*/virology ; Hepatitis B virus*/physiology ; Hepatitis B virus*/genetics ; Ubiquitination* ; Signal Transduction* ; Interferon-beta*/genetics; Humans ; Cell Line, Tumor ; Hepatitis B/virology ; Hepatitis B/complications
    • Abstract:
      A newly discovered E3 ubiquitin ligase, UBR7, plays a crucial role in histone H2BK120 monoubiquitination. Here, we report a novel function of UBR7 in promoting hepatitis B virus (HBV) pathogenesis, which further leads to HBV-induced hepatocellular carcinoma (HCC). Transcriptomics analysis from HCC patients revealed the deregulation of UBR7 in cancer. Remarkably, targeting UBR7, particularly its catalytic function, led to a significant decrease in viral copy numbers. We also identified the speckled family protein Sp110 as an important substrate of UBR7. Notably, Sp110 has been previously shown to be a resident of promyelocytic leukemia nuclear bodies (PML-NBs), where it remains SUMOylated, and during HBV infection, it undergoes deSUMOylation and exits the PML body. We observed that UBR7 ubiquitinates Sp110 at critical residues within its SAND domain. Sp110 ubiquitination downregulates genes in the type I interferon response pathway. Comparative analysis of RNA-Seq from the UBR7/Sp110 knockdown data set confirmed that the IFN-β signaling pathway gets deregulated in HCC cells in the presence of HBV. Single-cell RNA-Seq analysis of patient samples further confirmed the inverse correlation between the expression of Sp110/UBR7 and the inflammation score. Notably, silencing of UBR7 induces IRF7 phosphorylation, thereby augmenting interferon (IFN)-β and the downstream interferon-stimulated genes (ISGs). Further, wild-type but not the ubiquitination-defective mutant of Sp110 could be recruited to the type I interferon response pathway genes. Our study establishes a new function of UBR7 in non-histone protein ubiquitination, promoting viral persistence, and has important implications for the development of therapeutic strategies targeting HBV-induced HCC.
    • Contributed Indexing:
      Keywords: E3 ubiquitin ligase; HBV; HCC; IFN-β; ISGs; Sp110; UBR7; hepatis B virus; hepatocellular carcinoma; interferon-stimulated genes; interferon-β
    • Accession Number:
      EC 2.3.2.27 (Ubiquitin-Protein Ligases)
      77238-31-4 (Interferon-beta)
    • Publication Date:
      Date Created: 20240628 Date Completed: 20241108 Latest Revision: 20241108
    • Publication Date:
      20241114
    • Accession Number:
      10.1021/acsinfecdis.4c00213
    • Accession Number:
      38938101